Evidence map›Paper›PMID 34386328›Full record

ArticleActa pharmaceutica Sinica. B2021

Inhibition of LIM kinase reduces contraction and proliferation in bladder smooth muscle.

Qingfeng Yu, Chengjie Wu, Yeda Chen, Bingsheng Li, Ruixiao Wang, Ru Huang, Xuechun Li, Di Gu, Xiaolong Wang, Xiaolu Duan and 5 more

Open access · diamondAbstract read
In one paragraph

Article in Acta pharmaceutica Sinica. B, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
3.1field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 2 countries.

Qingfeng YuDepartment of Urology and Guangdong Key Laboratory of Urology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510230, China.
Chengjie WuDepartment of Urology and Guangdong Key Laboratory of Urology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510230, China.
Yeda ChenDepartment of Urology and Guangdong Key Laboratory of Urology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510230, China.
Bingsheng LiDepartment of Urology, University Hospital, LMU Munich, Munich 81377, Germany.
Ruixiao WangDepartment of Urology, University Hospital, LMU Munich, Munich 81377, Germany.
Ru HuangDepartment of Urology, University Hospital, LMU Munich, Munich 81377, Germany.
Xuechun LiDepartment of Urology and Guangdong Key Laboratory of Urology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510230, China.
Di GuDepartment of Urology and Guangdong Key Laboratory of Urology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510230, China.
Xiaolong WangDepartment of Urology, University Hospital, LMU Munich, Munich 81377, Germany.
Xiaolu DuanDepartment of Urology and Guangdong Key Laboratory of Urology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510230, China.
Shujue LiDepartment of Urology and Guangdong Key Laboratory of Urology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510230, China.
Yang LiuDepartment of Urology and Guangdong Key Laboratory of Urology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510230, China.
Wenqi WuDepartment of Urology and Guangdong Key Laboratory of Urology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510230, China.
Martin HennenbergDepartment of Urology, University Hospital, LMU Munich, Munich 81377, Germany.
Guohua ZengDepartment of Urology and Guangdong Key Laboratory of Urology, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510230, China.
First Affiliated Hospital of Guangzhou Medical University · CNLMU Klinikum · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Overactive bladder (OAB) is the most bothersome symptom in lower urinary tract symptoms (LUTS). Current pharmacologic treatment aims to inhibit detrusor contraction; however, shows unsatisfied efficacy and high discontinuation rate. LIM kinases (LIMKs) promote smooth muscle contraction in the prostate; however, their function in the bladder smooth muscle remains unclear. Here, we studied effects of the LIMK inhibitors on bladder smooth muscle contraction and proliferation both

Indexed as

4E-BP1, 4E-binding protein 1ADF, actin depolymerizing factorsBladder smooth muscle contractionBOO, bladder outlet obstructionBPH, benign prostatic hyperplasiaCCK-8, Cell Counting Kit-8Cofilin phosphorylationCt, number of cyclesDMSO, dimethyl sulfoxideEdU, 5-ethynyl-2′-deoxyuridineGAPDH, glyceraldehyde 3-phosphate dehydrogenaseHBSMCs, human bladder smooth muscle cellsH&E, hematoxylin and eosinHRP, horseradish peroxidaseLIMKLIMKs, LIM kinasesLower urinary tract symptoms (LUTS)LUTS, lower urinary tract symptomsMLC, myosin light chainMW, molecular weightMYPT1, myosin-binding subunitOAB, overactive bladderOveractive bladder (OAB)PCNA, proliferating cell nuclear antigenRT-qPCR, reverse transcription and quantitative polymerase chain reactionsiRNA, small interfering RNASTK16, serine/threonine kinase 16TESK1, testicular protein kinase 1TXA2, thromboxane A2WST-8, 2-(2-methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2H-tetrazolium monosodium salt

Identifiers

PMID34386328
PMCPMC8343115
OpenAlexW3120493208

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.